380 related articles for article (PubMed ID: 37445722)
21. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
22. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Xu J; Zeng LF; Shen W; Turchi JJ; Zhang ZY
Biochem Biophys Res Commun; 2013 Oct; 439(4):586-90. PubMed ID: 24041688
[TBL] [Abstract][Full Text] [Related]
23. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
24. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
[TBL] [Abstract][Full Text] [Related]
25. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
26. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
27. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor.
Yart A; Laffargue M; Mayeux P; Chretien S; Peres C; Tonks N; Roche S; Payrastre B; Chap H; Raynal P
J Biol Chem; 2001 Mar; 276(12):8856-64. PubMed ID: 11134009
[TBL] [Abstract][Full Text] [Related]
28. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice.
Schneeberger VE; Luetteke N; Ren Y; Berns H; Chen L; Foroutan P; Martinez GV; Haura EB; Chen J; Coppola D; Wu J
Carcinogenesis; 2014 Aug; 35(8):1717-25. PubMed ID: 24480804
[TBL] [Abstract][Full Text] [Related]
29. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
30.
Hill KS; Roberts ER; Wang X; Marin E; Park TD; Son S; Ren Y; Fang B; Yoder S; Kim S; Wan L; Sarnaik AA; Koomen JM; Messina JL; Teer JK; Kim Y; Wu J; Chalfant CE; Kim M
Mol Cancer Res; 2019 Feb; 17(2):583-593. PubMed ID: 30355677
[TBL] [Abstract][Full Text] [Related]
31. Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).
Karachaliou N; Cardona AF; Bracht JWP; Aldeguer E; Drozdowskyj A; Fernandez-Bruno M; Chaib I; Berenguer J; Santarpia M; Ito M; Codony-Servat J; Rosell R
EBioMedicine; 2019 Jan; 39():207-214. PubMed ID: 30473379
[TBL] [Abstract][Full Text] [Related]
32. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.
Furcht CM; Muñoz Rojas AR; Nihalani D; Lazzara MJ
Oncogene; 2013 May; 32(18):2346-55, 2355.e1-10. PubMed ID: 22777356
[TBL] [Abstract][Full Text] [Related]
33. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP
Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324
[TBL] [Abstract][Full Text] [Related]
34. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
35. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
36. mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition.
Chen Y; Li WW; Peng P; Zhao WH; Tian YJ; Huang Y; Xia S; Chen Y
Acta Pharmacol Sin; 2019 Aug; 40(8):1085-1094. PubMed ID: 30796356
[TBL] [Abstract][Full Text] [Related]
37. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
[TBL] [Abstract][Full Text] [Related]
38. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
39. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
40. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]